Stocks and Investing Stocks and Investing
Wed, May 24, 2023

Keay Nakae Reiterated (ARWR) at Strong Buy and Held Target at $60 on, May 24th, 2023


Published on 2024-10-28 03:58:28 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, May 24th, 2023.

Keay has made no other calls on ARWR in the last 4 months.



There are 10 other peers that have a rating on ARWR. Out of the 10 peers that are also analyzing ARWR, 3 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $40 on, Friday, May 12th, 2023
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $40 on, Wednesday, May 3rd, 2023
  • William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023


These are the ratings of the 7 analyists that currently disagree with Keay


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $60 on, Wednesday, May 3rd, 2023
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $73 on, Wednesday, May 3rd, 2023
  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, February 10th, 2023
  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $52 on, Tuesday, February 7th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023
Contributing Sources